Search research articles
Contact Us
Filters
Showing results (61-70 of 93) with videos related to
Page
of 10
Sort By:
Targeted Oncology
|
January 25, 2013
Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept
Nicole Shonka, Yuji Piao, Mark Gilbert, et al.
Neuro-Oncology
|
November 7, 2017
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
Antonio Omuro, Gordana Vlahovic, Michael Lim, et al.
Journal of Neuro-Oncology
|
December 29, 2022
ABTC-0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC-0449
Andrew E Sloan, Charles J Nock, Xiaobu Ye, et al.
Investigational New Drugs
|
July 14, 2005
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
Susan M Chang, Patrick Wen, Timothy Cloughesy, et al.
Neuro-Oncology
|
August 31, 2016
Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy
HuyTram N Nguyen, Amy Lie, Tie Li, et al.
Neuro-Oncology
|
May 12, 2011
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab
Jeffrey S Wefel, Timothy Cloughesy, James L Zazzali, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 4, 2018
Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment
Xiao-Tang Kong, Nhung T Nguyen, Yoon J Choi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2007
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study
Monica E Loghin, Michael D Prados, Patrick Wen, et al.
Neuro-Oncology
|
March 15, 2006
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study
Michael D Prados, Kathleen Lamborn, W K A Yung, et al.
The Lancet. Oncology
|
May 5, 2012
Phase 2 trial design in neuro-oncology revisited: a report from the RANO group
Evanthia Galanis, Wenting Wu, Timothy Cloughesy, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 93) with videos related to
Sort By:
Page
of 10
Targeted Oncology
|
January 25, 2013
Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept
Nicole Shonka, Yuji Piao, Mark Gilbert, et al.
Neuro-Oncology
|
November 7, 2017
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
Antonio Omuro, Gordana Vlahovic, Michael Lim, et al.
Journal of Neuro-Oncology
|
December 29, 2022
ABTC-0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC-0449
Andrew E Sloan, Charles J Nock, Xiaobu Ye, et al.
Investigational New Drugs
|
July 14, 2005
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
Susan M Chang, Patrick Wen, Timothy Cloughesy, et al.
Neuro-Oncology
|
August 31, 2016
Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy
HuyTram N Nguyen, Amy Lie, Tie Li, et al.
Neuro-Oncology
|
May 12, 2011
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab
Jeffrey S Wefel, Timothy Cloughesy, James L Zazzali, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 4, 2018
Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment
Xiao-Tang Kong, Nhung T Nguyen, Yoon J Choi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2007
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study
Monica E Loghin, Michael D Prados, Patrick Wen, et al.
Neuro-Oncology
|
March 15, 2006
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study
Michael D Prados, Kathleen Lamborn, W K A Yung, et al.
The Lancet. Oncology
|
May 5, 2012
Phase 2 trial design in neuro-oncology revisited: a report from the RANO group
Evanthia Galanis, Wenting Wu, Timothy Cloughesy, et al.
Page
of 10